問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Cardiovascular Diseases

Chi Mei Medical Center (在職)

Division of Cardiovascular Diseases

Chi Mei Medical Center

Division of Cardiovascular Diseases

更新時間：2023-09-19

洪俊聲
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪俊聲

List

29Cases

2024-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2021-05-01 - 2024-09-19

Phase II/III

Completed
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40%

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD4831

Participate Sites
14Sites

Not yet recruiting1Sites

Recruiting11Sites

Terminated1Sites

Study ended1Sites

黃瑞仁
National Taiwan University Hospital

Division of Cardiovascular Diseases

2025-07-01 - 2030-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease (ASCVD)

  • Test Drug

    tablet

Participate Sites
23Sites

Recruiting23Sites

2024-03-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

  • Condition/Disease

    Heart Failure

  • Test Drug

    capsule

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting10Sites

2024-04-15 - 2026-12-31

Phase II

Active
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria

  • Condition/Disease

    Chronic Kidney Disease and Albuminuria

  • Test Drug

    capsule

Participate Sites
8Sites

Not yet recruiting6Sites

Recruiting2Sites

2023-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting5Sites

2024-04-01 - 2026-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-07-01 - 2026-01-31

Phase III

Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

  • Condition/Disease

    Hypercholesterolemia、 Familial Hypercholesterolemia

  • Test Drug

    MK-0616

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia

  • Condition/Disease

    Hypercholesterolemia

  • Test Drug

    tablet

Participate Sites
10Sites

Recruiting10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB